Clinical study of Rosiglitazone(Avandia)in treating type 2 diabetes mellitus with Metabolic Syndrome.
- VernacularTitle:罗格列酮治疗伴有代谢综合征2型糖尿病的疗效观察
- Author:
Chunru YIN
;
Zhimin LI
;
Na CHENG
;
Al ET
;
- Publication Type:Journal Article
- Keywords:
Type 2 diabetes;
Rosiglitazone;
Metabolic syndrome
- From:
Chinese Journal of Practical Internal Medicine
2006;0(S1):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficieney and safety of Rosiglitazone(Avandia)Monotherapy or combi- nation with oral hypoglycemic agents in treating type 2 diabetes mellitus with Metabolic syndrome.Methods 68 type 2 diabetic patients with Metabolic syndrome were assigned to receive Avandia treatment at doses of 4mg for 12 weeks.Re,. sults Avandia used alone or in combination with oral hypoglycemic agents significantly reduced fasting plasma glucose (FBG)and fasting plasma insulin(FINS).Mean glycosylated hemoglobin values were significantly deereaseel.Home- ostasis model assessmen indicate that RSG reduced insulin resistance.There were statistically significiant decrease in systolic blood pressure(SBP)and diastolic blood pressure(DBP).No significant side-effects on kidney and liver function were found.Conclusion Avandia is an insulin sensitizer that is effective and safe on the treatment of Type 2 Diabetes with Metabolic syndrome by decreasing blood glucose and blood lipid,improving insulin resistance,and main- taining the function of pancreatic island cells.
